dc.date.accessioned | 2013-03-12T12:36:46Z | |
dc.date.available | 2013-03-12T12:36:46Z | |
dc.date.issued | 2012 | en_US |
dc.date.submitted | 2012-04-12 | en_US |
dc.identifier.citation | Karlstad, Ida Marie, Tell, Nicolai, . Telomerase - et potensielt angrepspunkt i kampen mot kreft. Prosjektoppgave, University of Oslo, 2012 | en_US |
dc.identifier.uri | http://hdl.handle.net/10852/29353 | |
dc.description.abstract | Background: Telomerase is a necessity for infinite cell division in cancer cells, and high telomerase activity is present in as much as 90 % of human cancers. Hence telomerase has become an attractive target in cancer therapy because it suggests a universal cure for cancer. We summarized research done on the vaccine GV1001 and the telomerase inhibitor Imetelstat in prostate, pancreas and lung cancer. Methods: We reviewed finished and ongoing clinical trials on GV1001 and Imetelstat; and preclinical trials on Imetelstat. Results: Preclinical trials on Imetelstat show that it is a potent inhibitor of cancer growth. It also targets tumor initiating cells (TIC). Clinical trials on GV1001 have shown that it’s a safe treatment. It also induces immune response in majority of patients and phase I/II studies suggest an increased overall survival in the immune responders. Even though one clinical phase III trial on GV1001 has shown negative results, other studies suggest a positive additive effect when combined with chemo and radiotherapy. Conclusion: Therapy targeting telomerase is safe. We believe telomerase-targeted therapy can be an important supplement to other cancer therapy even though it doesn’t seem promising as single treatment. | eng |
dc.language.iso | nob | en_US |
dc.subject | kirurgi | |
dc.title | Telomerase - et potensielt angrepspunkt i kampen mot kreft | en_US |
dc.type | Master thesis | en_US |
dc.date.updated | 2012-08-21 | en_US |
dc.creator.author | Karlstad, Ida Marie | en_US |
dc.creator.author | Tell, Nicolai | en_US |
dc.subject.nsi | VDP::780 | en_US |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&rft.au=Karlstad, Ida Marie&rft.au=Tell, Nicolai&rft.title=Telomerase - et potensielt angrepspunkt i kampen mot kreft&rft.inst=University of Oslo&rft.date=2012&rft.degree=Prosjektoppgave | en_US |
dc.identifier.urn | URN:NBN:no-30860 | en_US |
dc.type.document | Prosjektoppgave | en_US |
dc.identifier.duo | 154035 | en_US |
dc.contributor.supervisor | Trond Buanes | en_US |
dc.identifier.bibsys | 122407504 | en_US |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/29353/3/Prosjekt-Karlstadf.pdf | |